Report card of three months of negotiation on the landing of anticancer drugs: 620000 boxes have been used nationwide

Since October last year, the national health insurance bureau announced that 17 kinds of anti-cancer drugs have been included in the list of medical insurance reimbursement, the average decline of anti-cancer drugs has been nearly half, so that many patients who have been unable to use drugs can also use "life-saving drugs" Wang Hesheng, deputy director of the National Health Commission, said at a national teleconference on January 21 that 620000 boxes of negotiated anticancer drugs had been used nationwide as of January 10 On October 10, 2018, the state health insurance bureau issued the notice on including 17 kinds of drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalog After more than three months of negotiation, 17 kinds of anticancer drugs have been included in the medical insurance reimbursement catalog, including 12 solid tumor drugs and 5 blood tumor drugs, which are clinically necessary, effective and urgently needed by the insured, involving multiple cancer types such as non-small cell lung cancer, renal cancer, colorectal cancer, melanoma, lymphoma, etc Compared with the average retail price, the average decrease of 17 negotiated drugs was 56.7% The payment standard of most imported drugs after negotiation was lower than the market price of surrounding countries or regions, with an average decrease of 36% Since the payment standard of most imported drugs after negotiation is lower than the market price of surrounding countries or regions, the burden of drug use for cancer patients in China has been greatly reduced In order to ensure that patients can reap dividends effectively, the state health insurance bureau said that it will coordinate with relevant departments to strengthen the guidance for doctors' drug use The National Health Insurance Bureau and the health care Commission immediately began their work In terms of medical insurance, it is stipulated that the cost of anticancer drugs negotiated by 17 countries will not be included in the total amount control scope, the cost of reasonable use will be accounted separately according to the provisions, and relevant factors will also be taken into account when formulating the total budget in 2019 In terms of the use of medical institutions, the health and Health Commission issued a notice, requiring the tertiary general hospital and tumor specialized hospitals at all levels registered in the oncology department to timely provide negotiation drugs according to the clinical needs, and requiring weekly reports of procurement and use progress According to statistics, as of January 3, 2019, 1386 hospitals in 31 provinces and Xinjiang production and Construction Corps reported relevant data, most of which purchased negotiation anticancer drugs according to their needs As of January 10, three months after the document was issued, 620000 boxes of negotiation anticancer drugs had been used nationwide Wang Hesheng said that the National Health Commission has organized the National Cancer Center to develop the national monitoring network for the clinical application of anti-tumor drugs In the next step, it will continue to urge the health departments and medical institutions around the country to regularly report, analyze and feed back the monitoring data, so as to promote the rational clinical use of drugs.